Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF-B

VEGF-B

Brief Information

Name:Vascular endothelial growth factor B
Target Synonym:VEGF-related factor,VRF,VEGFB,VEGF-B,VEGFL,Vascular Endothelial Growth Factor B
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
VE6-H5225 Human Human VEGF-B Protein, His Tag
VE6-H5225-structure
VE6-H5225-sds

Part of Bioactivity data

VE6-H5225-MALS-HPLC
Human VEGF-B, His TagHuman VEGF-B, His Tag (Cat. No. VE6-H5225) ELISA bioactivity

Measured by its binding ability in a functional ELISA. Immobilized Human VEGF-B, His Tag (Cat. No. VE6-H5225) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R1 with a linear range of 2-32 ng/mL (QC tested).

Synonym Name

VRF,VEGFL,VEGFB,VEGF-B

Background

Vascular endothelial growth factor B (VEGFB) is also known as VEGF-related factor (VRF), is a secreted O-glycosylated protein, which belongs to the PDGF/VEGF growth factor family. VEGFB is expressed in all tissues except liver. Highest levels found in heart, skeletal muscle and pancreas. VEGFB is growth factor for endothelial cells. VEGF-B seems to play a role only in the maintenance of newly formed blood vessels during pathological conditions. VEGF-B also plays an important role on several types of neurons. It is important for the protection of neurons in the retina and the cerebral cortex during stroke and of motoneurons during motor neuron diseases such as amyotrophic lateral sclerosis.VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ziv-aflibercept BAY-865321; AVE-0005 Approved Regeneron Pharmaceuticals Inc, Sanofi Zaltrap Japan Colorectal Neoplasms Sanofi 2012-08-03 Ovarian Neoplasms; Solid tumours; Ascites; Lung Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Lymphoma; Neoplasm Metastasis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CSL-346 2H-10; CSL-346 Phase 2 Clinical Csl Ltd Diabetes Mellitus, Type 2; Diabetic Nephropathies Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message